News

Sling Therapeutics Announces Positive Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease

Ann Arbor, MI, January 14, 2025 /PR NEWSWIRE/ – Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced topline efficacy and safety data from the Phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe TED.

Sling Therapeutics to Announce Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease at the 43rd Annual J.P. Morgan Healthcare Conference

ANN ARBOR, Mich., Jan. 13, 2025 /PRNewswire/ — Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye disease (TED), will announce topline data from the Phase 2b/3 LIDS trial of…

Sling Therapeutics Appoints Andrew Guggenhime to its Board of Directors

ANN ARBOR, Mich., Jan. 7, 2025 /PRNewswire/ — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced the appointment of Andrew Guggenhime, an experienced…

Sling Therapeutics Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

ANN ARBOR, Mich., Jan. 6, 2025 /PRNewswire/ — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced that Raymond Douglas, M.D., Ph.D., Chief Scientific…

Sling Therapeutics to Participate in Upcoming Investor Conferences

Ann Arbor, MI, November 8, 2023 — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), will be participating in three upcoming investor conferences in November…

Sling Therapeutics Announces Publication Demonstrating Attenuation of Pathologic Bone Marrow Activity with Linsitinib in a Mouse Model of Thyroid Eye Disease

– Linsitinib inhibited the formation of CD4+ T-cells in bone marrow, which are upregulated and clinically relevant in Thyroid Eye Disease (TED) – – Ongoing global Phase 2b LIDS clinical trial evaluating linsitinib for treatment of active, moderate to severe…

Sling Therapeutics Appoints Raymond Douglas, M.D., Ph.D., as Chief Scientific Officer

– Dr. Raymond Douglas, renowned thyroid eye disease specialist, joins the management team and brings extensive clinical and development experience across the spectrum of TED therapies – – Appointment supports the development of company’s lead asset, linsitinib, through the ongoing…

Sling Therapeutics to Participate in the Stifel Virtual I&I Summit

Ann Arbor, MI, September 13, 2023 — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), will be participating at the Stifel I&I summit, held virtually,…

Sling Therapeutics Presents Preclinical Data Demonstrating Treatment with Linsitinib Limits Progression of Thyroid Eye Disease at 45th Annual Meeting of European Thyroid Association

– Results highlighted in oral presentation show linsitinib significantly limited disease severity in early- and late-stage TED mouse models and prevented development of autoimmune response – – Company currently evaluating linsitinib in ongoing global Phase 2b LIDS clinical trial in…

Sling Therapeutics Presents Data Demonstrating Linsitinib Prevents Thyroid Eye Disease Progression in a Mouse Model at ENDO 2023

– Treatment with linsitinib in a clinically relevant mouse model demonstrated a significant reduction in autoimmune response and classical Thyroid Eye Disease (TED) symptoms, independent of TED severity – – Ongoing global Phase 2b LIDS clinical trial evaluating linsitinib for…